ImpediMed Says Reimbursement Supported by Increased Insurance Coverage for Lymphoedema Testing using Bioimpedance Spectroscopy

MT Newswires Live

Dec 04, 2025

ImpediMed (ASX:IPD) said reimbursement for lymphoedema testing using its SOZO Digital Health Platform was supported by a further three US state-based insurers and one multi-state insurer, taking measures recognizing bioimpedance spectroscopy as medically necessary for the assessment of lymphoedema, according to a Thursday Australian bourse filing.

This led to the total covered lives increasing to 314.5 million from 304 million, per the filing.

The firm's shares rose 1% in recent trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588107167"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588107167\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588107167?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588107167","market":"us","top_or_hot":-1,"title":"ImpediMed Says Reimbursement Supported by Increased Insurance Coverage for Lymphoedema Testing using Bioimpedance Spectroscopy","media":"MT Newswires Live","content":"<html><body><p> ImpediMed (ASX:IPD) said reimbursement for lymphoedema testing using its SOZO Digital Health Platform was supported by a further three US state-based insurers and one multi-state insurer, taking measures recognizing bioimpedance spectroscopy as medically necessary for the assessment of lymphoedema, according to a Thursday Australian bourse filing.</p><p>This led to the total covered lives increasing to 314.5 million from 304 million, per the filing.</p><p>The firm's shares rose 1% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImpediMed Says Reimbursement Supported by Increased Insurance Coverage for Lymphoedema Testing using Bioimpedance Spectroscopy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImpediMed Says Reimbursement Supported by Increased Insurance Coverage for Lymphoedema Testing using Bioimpedance Spectroscopy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-04 10:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> ImpediMed (ASX:IPD) said reimbursement for lymphoedema testing using its SOZO Digital Health Platform was supported by a further three US state-based insurers and one multi-state insurer, taking measures recognizing bioimpedance spectroscopy as medically necessary for the assessment of lymphoedema, according to a Thursday Australian bourse filing.</p><p>This led to the total covered lives increasing to 314.5 million from 304 million, per the filing.</p><p>The firm's shares rose 1% in recent trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPD.AU","symbol_name":"IMPEDIMED LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588107167","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588107167","pubTimestamp":1764814869,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ImpediMed  said reimbursement for lymphoedema testing using its SOZO Digital Health Platform was supported by a further three US state-based insurers and one multi-state insurer, taking measures recognizing bioimpedance spectroscopy as medically necessary for the assessment of lymphoedema, according to a Thursday Australian bourse filing.This led to the total covered lives increasing to 314.5 million from 304 million, per the filing.The firm's shares rose 1% in recent trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPD.AU":"IMPEDIMED LTD","BK7007":"医疗保健设备","BK7509":"中概股"},"translate_title":"ImpediMed表示，使用生物阻抗谱进行淋巴水肿检测的保险范围增加支持了报销","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPD.AU":1},"content_text":"ImpediMed (ASX:IPD) said reimbursement for lymphoedema testing using its SOZO Digital Health Platform was supported by a further three US state-based insurers and one multi-state insurer, taking measures recognizing bioimpedance spectroscopy as medically necessary for the assessment of lymphoedema, according to a Thursday Australian bourse filing.This led to the total covered lives increasing to 314.5 million from 304 million, per the filing.The firm's shares rose 1% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}